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Background: Although available evidence relating to its effectiveness is weak, acupuncture is used as an alternative
therapy for stress urinary incontinence. We report a protocol of a randomized controlled trial using
electroacupuncture (the passing of a weak current between inserted acupuncture needles) to treat women with
pure stress urinary incontinence.
Methods/Design: This is a large-scale multicenter subject-blinded randomized controlled trial. A total of 500
women with pure stress urinary incontinence will be randomly assigned to two groups: a treatment group and a
control group. The treatment group will receive electroacupuncture with deep needling at acupuncture points
BL33 and BL35. The control group will receive sham electroacupuncture with non-penetrating needling at sham
locations for the acupuncture points of BL33 and BL35. Participants will be given three sessions a week for 6 weeks.
A 24-week-long follow-up will be conducted. The primary outcome will be the change in amount of urine leakage
at the sixth week from a baseline measured by a 1-h pad test. The secondary outcomes include: the 72-h
incontinence episode frequency based on a 72-h bladder diary; the score of International Consultation on
Incontinence Questionnaire-Urinary Incontinence Short Form; the degree of urinary incontinence based on a 72-h
bladder diary; self-assessment of the therapeutic effect; weekly consumption of pads; application of other
treatments for stress urinary incontinence; and subgroup analysis stratified by incontinence severity. The safety of
electroacupuncture will also be assessed.
Discussion: This trial will help to identify whether electroacupuncture is effective for stress urinary incontinence,
and, if so, whether it is a therapeutic effect rather than a placebo effect.
Trial Registration: Clinical Trials.gov NCT01784172
Keywords: Electroacupuncture, Pure stress urinary incontinence, Efficacy, RCT, Study protocolBackground
Stress urinary incontinence (SUI), defined as the invol-
untary leakage of urine on effort or exertion, or on
sneezing or coughing [1], is a common complaint among
adult women. It is generally considered that urinary in-
continence (UI) is a prevalent cross-cultural healthcare* Correspondence: liuby@mail.cintcm.ac.cn
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reproduction in any medium, provided the orproblem. The global median prevalence of female UI
was found to be 27.6% (range: 4.8-58.4%) [2], among
which SUI accounted for about 50% [2,3]. Prevalence of
SUI increases with age, and a global annual incidence of
4% to 10% was estimated in longitudinal studies [4]. SUI
affects not only a patient’s physical health but also her
social and psychological wellbeing. Patients are more
likely to become depressed and are more prone to self-
abasement than other women because of the uncon-
trollable leakage of urine. This makes them nervousThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activities. These negative quality-of-life effects are
greater than those resulting from some major chronic
conditions (diabetes, hyperlipidemia, and chronic kidney
disease) [5].
The International Consultation on Urological Diseases
(ICUD) recommends lifestyle regulation, behavior ther-
apy, pelvic floor muscle training (PFMT), and functional
electrical stimulation as conventional therapies for mild
and moderate female SUI. A systematic review sup-
ported PFMT as a conservative grade-A recommended
therapy for female SUI with a 30-60% effective rate;
however, for it to be maximally effective it needs to be
practiced for at least 3 months [6]. Additionally, the
positive effects of PFMT are closely related with patient
compliance [7], which decreases with the extension of
training time. PFMT is seldom used in China since
skilled physiotherapists are rare. For moderate to severe
SUI, a mid urethral sling with surgical mesh is widely
used. However, the use of surgical mesh increases
adverse events such as pain, infection, dysuria, and
neuromuscular problems. A safety communication from
the U.S. Food and Drug Administration (FDA) on ser-
ious complications associated with transvaginal place-
ment of surgical mesh for pelvic organ prolapse was
issued on 13 July 2011 [8]. Several randomized controlled
trials (RCTs) showed that acupuncture, by decreasing
urine leakage and improving patients’ quality of life,
maybe an alternative therapy for SUI [9,10]. However,
because of the limited evidence [11], high-quality RCTs
are needed to assess the efficacy of acupuncture for
treating SUI.
We have designed a multicenter RCT on pure SUI
patients that do not exhibit symptoms suggestive of
overactive bladder or voiding dysfunction [12]. Using
sham electroacupuncture (EA) as control, the trial aims
to identify the efficacy of EA by answering two ques-
tions: (1) Is EA effective for women with pure SUI? and
(2) If effective, is it a therapeutic effect rather than a
placebo effect? Additionally, we intend to establish the
safety and acceptance of EA in women with pure SUI.




This is a multicenter subject-blinded randomized con-
trolled trial comparing EA with sham EA. Five hundred
women with pure SUI will be recruited from the follow-
ing 12 hospitals in China: Guang’an men Hospital of
China Academy of Chinese Medical Sciences (CACMS);
Xiyuan Hospital of CACMS; Dongzhimen Hospital affili-
ated to Beijing University of Chinese Medicine; Yueyang
Hospital of Integrated Traditional Chinese and WesternMedicine affiliated to Shanghai University of Traditional
Chinese Medicine (TCM); West China Hospital of
Sichuan University; First Teaching Hospital of Tianjin
University of TCM; First Hospital of Hunan University
of Chinese Medicine; Hengyang Hospital affiliated to
Hunan University of Chinese Medicine; Hubei Provincial
Hospital of TCM; Jiangsu Province Hospital of TCM;,
Shanxi Province Hospital of TCM; and Shanxi Hospital
of Integrated Traditional and Western Medicine. Partici-
pants will be randomly assigned (on a 1:1 ratio) to the
EA group or the sham EA group by a central rando-
mization system performed by the Clinical Evaluation
Center of the CACMS in Beijing. The randomization
sequence will be generated by the ‘proc plan’ procedure
of the SAS9.3 analytic software according to center-
stratified, block randomization with a block size of six.
Random number and group assignment will be offered
by telephone, mobile phone, or website from the Clinical
Evaluation Center of the CACMS. In this study, parti-
cipants, outcome assessors, and statisticians will be
blinded to treatment allocation. The flowchart and
study design schedule are presented in Figure 1 and
Table 1, respectively.
Ethics
The study is in accordance with the principles of the
Declaration of Helsinki, and has been approved by the
ethics committee boards of the participating hospitals
(Ethics approval numbers: 2012EC007; 2013XL001-2;
ECPJ-BDY-2013-04; 2013–033; 2013–7; TYLL2013; HN-
LL-KY-2013-001-01; 2013EC001; HBZY2013-C007-01;
2013NL-013-04; 2013–02; 2012EC007) (Additional file 1).
Written informed consent will be obtained from each sub-
ject before the patients enter the trial.
Participants
The trial plans to recruit 500 women with pure SUI
using research nurses or students majoring in acupunc-
ture to do the recruiting.
Inclusion criteria are: (1) aged 40–75 years; (2) invol-
untary leakage of urine on effort, exertion, sneezing or
coughing that stops when the stress ends [13]; (3) visible
involuntary leakage from the urethra synchronous with
increased abdominal pressure, or a pad weight gain >1 g
in a 1-h pad test [13]; (4) no symptoms of urinary fre-
quency and urgency; and (5) voluntarily join the research
and sign the informed consent.
Exclusion criteria are: (1) urge urinary incontinence,
mixed urinary incontinence, or overflow urinary incon-
tinence; (2) having ever undergone an operation for
urinary incontinence or on the pelvic floor; (3) female
genital prolapse greater than degree 2; (4) symptomatic
urinary tract infection; (5) residual urinary volume (RUV) >
30 mL; (6) maximum flow rate (Qmax) ≤20 mL/s; (7)
Figure 1 Trial flow chart.
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ceiving specific treatment for SUI, or taking medicine
that may affect bladder function; (9) serious cardiovas-
cular, cerebral, liver, kidney, or psychiatric disease, dia-
betes, multiple system atrophy, injury of cauda equina,
or myeleterosis; (10) pregnancy or lactation; and (11)having a cardiac pacemaker, a metal allergy, or a severe
needle phobia.
Interventions
Acupuncture will be performed by registered acupunc-
turists with over 2 years of experience.
Table 1 Study design schedule
Period Screening Baseline Treatment (w1-6) Follow-up (w7-30)
Week (W) W-1 W0 W2 W3 W4 W6 W15 W16 W17 W18 W27 W28 W29 W30
Eligibility X
Informed consent X
Demography and medical history X
Physical examination X
Laboratory test X
1-h pad test X X X
72-h bladder diary X X X X X X X X X X X X
Weekly consumption of pads X X X X X X X X X X X X
Application of other treatments for SUI X X X X X X X X X X X X
ICIQ-UI Short form X X X X
Self-report assessment of therapeutic effect X X X X X
Safety of EA X X X
Discomfort and acceptance of EA X X
Assessment of blind method X X
Adverse event X X X X X X X X X X
Compliance X X X X X X X X X X
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Acupuncture points (bilateral Zhongliao BL33 and Huiyang
BL35) are selected based on evaluation of acupuncture
literature, our pilot study and consensus of 10 Chinese
acupuncture experts (Additional file 2). Before needling,
sterile adhesive pads will be pasted onto the selected
acupuncture points (for both groups, to ensure subject
blinding). The adhesive pads (10 mm in diameter, 5
mm thick) are made of a special sponge and have a
sticky side (Suzhou Medical Appliance Factory, China)
(Additional file 3). The needles (0.30 mm in diameter,
75 mm in length, Hwato Brand, Suzhou Medical Appli-
ance Factory, China) will be inserted at bilateral BL33
to a depth of 50–60 mm with an angle of 30-45° inward
and downward. Bilateral BL35 are needled to a depth of
50–60 mm outward and upward slightly. Deqi, the
needling sensations felt by a patient that indicates that
the point has been stimulated, will be achieved by lifting,
thrusting, and twirling the four needles evenly three times.
The electric stimulators (SDZ-V electroacupuncture ap-
paratus, Suzhou Medical Appliance Factory, China) will
connect the bilateral BL33 points and the bilateral BL35
points and a continuous wave of 50 Hz frequency and an
intensity of 1–5 mA will be applied. The intervention of
treatment group is shown in Additional file 4.
Control group (sham EA)
Sham points, which are 1 cun lateral to BL33 and BL35,
will be used to match each real point. Sham BL33 and
BL35 will be needled through adhesive pads to the skin(for the fixation of needles) without penetrating the skin
using blunt needles 0.30 mm in diameter, 25 mm in
length (Hwato Brand, Suzhou Medical Appliance Fac-
tory, China). The needles will then be lifted, thrust, and
twirled evenly three times to match the procedure
undertaken for the treatment group. The sham electrode
lines (Additional file 5), which look identical to the real
ones but with the inner metal wire cut off, will be ap-
plied to bilateral sham BL33 and bilateral sham BL35,
respectively, and a continuous wave of 50 Hz frequency
and an intensity of 5 mA will be applied. When turned
on, electric acupuncture apparatus looks normal but has
no current output. The intervention of the control group
is shown in Additional file 6.
For both groups, the needles will be retained for 30 min
for each treatment session. The participants will be treated
with EA three times a week, on alternate days, for six suc-
cessive weeks; 18 sessions for each patient in total.Permitted and prohibited concomitant treatments
Throughout the trial, participants will be discouraged
from undertaking any additional specific treatments for
SUI including: medications such as duloxetine and im-
ipramine; PFMT; feedback therapy; electrical or mag-
netic stimulation via pelvic floor, vagina or anus; and
transcutaneous electrical nerve stimulation to the pelvic
floor. For any unallowed treatment that has already been
used, relevant information should be recorded in the pa-
tient’s case report form.
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The primary outcome will be the change in the amount
of urine leakage at week 6 from the baseline, measured
by a 1-h pad test. The change at week 2 from the base-
line will also be assessed. The 1-h pad test will be
conducted based on the International Continence Soci-
ety (ICS) guidelines [14] at the baseline, at week 2, and
at week 6 (see Table 2). Secondary outcomes include
seven items, the details of which are listed in Table 2.Assessment of EA safety
Acupuncture is considered to be a generally safe pro-
cedure [15]; however, all adverse events will be
recorded in detail. In this study, EA-related adverse
events would mainly refer to broken needles, faintingTable 2 Trial outcomes
Primary outcome
Change in amount of urine leakage at week
6 from the baseline measured by 1-h pad test
Secondary outcomes
1. 72-h IEF
2. ICIQ-UI Short Form score
3. Severity of urinary incontinence
4. Self-report assessment of therapeutic effect
5. Weekly consumption of pads
6. Application of other treatment for SUI
(including drugs and other specialist treatment)
7. Subgroup analysis stratified by incontinence severitydue to the needling procedure, continuous post-needling
pain lasting >2 h, local infection, hematoma, bleeding, and
other events that can be caused by acupuncture (such
as fatigue, headache, insomnia, and dizziness).Assessment of the subject blinding success rate
Two of the study centers will be randomly selected to
measure the success rate of subject blinding via analyz-
ing questionnaire response (Figure 2). The questionnaire
will be completed by subjects within 5 min after any
treatment session in weeks 3 and 6. The percentage of
subjects from each group who believe that they received
a true EA treatment (regardless of whether they received
an actual true or actual sham treatment) will be recorded
as P1 in week 3 and P2 in week 6. The subject blindingTime point
Evaluated at week 6
Evaluated at weeks 6, 18, and 30. The change of average
72-h IEF from the baseline will be analyzed
Based on a 72-h bladder diary, the average 72-h IEF of week 6
is calculated by averaging the IEF of weeks 2, 4, and 6; values
of week 18 and 30 are calculated by averaging IEF of weeks
15–18 and 27–30, respectively
Evaluated at weeks 6, 18, and 30. The change of score
from the baseline will be analyzed
Evaluated at weeks 6, 18, and 30. Change in the number and
percentage of severity rating from the baseline will be analyzed
The most severe degree during weeks 2, 4, and 6 will be taken
as severity of urinary incontinence of week 6
The most severe degree during weeks 15–18 and weeks 27–30
will be taken as severity of urinary incontinence of week 18
and week 30, respectively
Evaluated at weeks 6, 18, and 30
A 4-point scale is used: no help, little help, medium help, and great help
Evaluated at weeks 6, 18, and 30. The change in average
consumption of pads from the baseline will be analyzed
The pads consumption of weeks 6, 18, and 30 will be calculated
by averaging the weekly usage of pads during weeks 1–6,
weeks 7–18, and weeks 19–30, respectively
Evaluated at weeks 6, 18, and 30. The number of patients who
used other treatments for SUI during the trial will be analyzed
between the two groups
Evaluated at weeks 6, 18, and 30
Stratified by incontinence severity at the baseline, the correlation
between the rating of incontinence severity and the treatment effect
will be analyzed. Different outcomes of treatment effect are used in
each evaluation: week 6, the change in amount of urine leakage at
week 6 from the baseline measured by 1-h pad test; week 18, the
change of average 72-h IEF at week 18 from the baseline; and week
30, the change of average 72-h IEF at week 30 from the baseline
Figure 2 Blind method assessment questionnaire.
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The difference in the subject blinding success rates
between the two groups will be analyzed.Statistical methods
Sample size calculation
We conducted a pilot study comparing the effects of
deep EA with shallow EA on women with SUI in
Guang’an men Hospital of CACMS between June 2011
and February 2012. Results from our pilot study revealed
that: compared with the baseline, the volume of urine
leakage from the 1-h pad test decreased by 2.10 g, with a
standard deviation of 2.26, after 4 weeks deep EA treat-
ment, and by 0.64 g with a standard deviation of 0.97
after 4 weeks shallow EA treatment [16]. We performed
sample size calculation according to results of our
pilot study because no placebo control trial has been
reported. A sample size of 117 in each group will be
sufficient to detect a clinically important difference of
1 g on the volume of urine leakage from a 1-h pad
test, assuming a standard deviation of 2.61 (consider-
ing a larger variability in multicenter trial, the pooled
standard deviation of pilot study 1.74 was expanded
by 1.5 times), using a one-tailed t-test of the difference
between means, a significance level of 5%, and a power
of 90%. The calculation is based on the assumption
that measurements on volume of urine leakage from a
1-h pad test are normally distributed. This number
has been increased to 140 per group (total of 280), to
allow for a predicted drop-out rate of 20%. As our
pilot study had a small sample size (n=40) and as we
will undertake subgroup analysis, we expanded thesample size to 500 cases (250 cases in each group) to
enhance the reliability of the study.
Statistical analysis
Statistical analysis will be performed by the Clinical
Evaluation Center of CACMS in Beijing and the Depart-
ment of Biostatistics, University of Washington, Seattle,
United States. The statistician will be blinded from the
allocation of groups. PASW Statistics 20.0 and SAS9.0
statistical software will be used for data analysis. The
level of significance is established at α<0.05 with a two-
tailed test.
The main objective is to compare the change in the
amount of urine leakage at week 6 from the baseline be-
tween the treatment group and the control group. The
null hypothesis is that the treatment group has the same
change as the control group, while the alternative hypoth-
esis is that the treatment group shows a greater decrease.
Continuous data will be represented by the average,
standard deviation, median, minimum value, and max-
imum value, whereas categorical data will be represented
by percentages. For comparison with the baseline, a
t-test or non-parametric test will be used for continuous
data, and non-parametric tests for categorical data. For
comparison of two independent samples: if the residual
are normally distributed, the analysis of covariance
(ANCOVA) will be used for the primary outcome and
subgroup analysis stratified by incontinence severity, a
t-test for other continuous data, and a chi-square test
for categorical data; if the residual are abnormally dis-
tributed, a non-parametric test will be used for both
continuous and categorical date. Detailed contents and
methods are as follows.
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distribution of both groups in every center will be
described. The total drop-out rate and the drop-out
rate due to adverse events, of both groups, will be
compared using Fisher’s exact test.
2. Analysis of baseline characteristics.
3. Analysis of compliance: The implementation of
protocol intervention will be compared between the
two groups. Compliance will be evaluated according
to the case report forms.
4. Analysis of efficiency: Intention-to-treat (ITT)
analysis will be used to assess the validity of the
study. Efficiency analysis will be based on the ITT
population which is defined as all randomized
participants. Missing data and non-compliance data
will be included in the efficiency analysis. Missing
data, from subjects without any treatment after
randomization, or without any valid data of
evaluation although treated, will be analyzed by
multiple imputation by the inverse probability
weighting method. Non-compliance data will be
analyzed by the instrumental variable.
5. Analysis of primary outcome: In this study, we will
use the change in the amount of urine leakage at
week 6 from the baseline as the primary outcome.
To adjust for baseline imbalance, a comparison of
the decreased value of urine leakage between the
groups will be done by ANCOVA using baseline and
centers as covariates, when the residual are normally
distributed. Meanwhile, a covariance model
including interactions between centers and group
will be made to analyze the center effect. Causes will
be further analyzed if any center effect is identified.
Comparison of decreased value of urine leakage
between groups will be analyzed by a non-
parametric test if the residual are abnormally
distributed with neglect of baseline balance.
6. Analysis of secondary outcomes:
A 72-h incontinence episode frequency (IEF), the
International Consultation on Incontinence
Questionnaire-Urinary Incontinence (ICIQ-UI)
Short Form score, and weekly consumption of pads
of weeks 6, 18, and 30 will be compared with their
respective baselines, and a t-test or non-parametric
test will be used for comparison among groups.
For severity of urinary incontinence based on a 72-h
bladder diary and a self-report assessment of
therapeutic effect, the case number and percentage
of each rank of weeks 6, 18, and 30 will be
compared with their baselines, and a chi-square test
or non-parametric test will be used for comparison
among groups.
Although we will exclude patients already receiving
some form of treatment for SUI at the trial outsetand will discourage participants from taking
additional treatments during the trial period, we
anticipate that some patients will not adhere to this.
In these instances the patients will record the
treatments received and/or medications taken and
the number of patients and treatment sessions of the
treatment period and two follow-up periods will be
described, and chi-square tests or non-parametric
tests will be used for comparison among groups.
To assess the effect of EA for different degrees of
SUI, subgroup analysis will be stratified by
incontinence severity measured by a 1-h pad test at
the baseline. In comparison among the groups,
changes in the amount of urine leakage at week 6
from the baseline will be analyzed by ANCOVA or
nonparametric tests. Changes in the 72-h IEF at
weeks 18 and 30 will be analyzed by covariance
analysis, non-parametric tests, or longitudinal
data model.
7. Analysis of safety: Adverse events will be listed and
analyzed using a chi-square test or Fisher’s exact
test. Severe adverse events should be listed in detail.
EA-related adverse events are to be listed in detail
and compared among groups.
8. Analysis of blind method: The number and
percentage of subjects choosing true EA in the
selected two centers will be established. A chi-
square test or non-parametric test will be used for
comparison among groups.
Discussion
This trial is expected to provide convincing evidence
that EA has an efficacy effect, and not a placebo effect,
for pure SUI. Extant literature shows that acupuncture is
probably effective for SUI; however, more evidence is
needed [10,17,18]. In existing studies, there are no ex-
amples of placebo being used as a control. To our know-
ledge, this is the first acupuncture trial applying sham
EA as a control in studying SUI. To maximally exclude
the placebo effect, rigorous methodological designs are
followed. We will use non-acupoints, non-penetrative
needling, and special electrode lines with no current out-
put for control. Points used in this trial are located on
the lumbosacral region; hence, participants are unable to
see their treatment. In addition, participants will receive
treatments alone at different times to avoid communica-
tion with each other. By following these methods, partic-
ipants can be blinded successfully, and the efficacy of EA
could be confirmed if the results of the treatment group
prove superior to the control group.
To evaluate the effect of SUI, a pad test, a bladder
diary and the ICIQ-SF are recommended by the ICS.
Among various pad test types, the 1-h pad test and the
24-h pad test [19] are most commonly used. These two
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a subjective assessment of SUI [20] or ICIQ-SF [21]; the
1-h pad test was adopted in this trial to maintain patient
compliance.
It is worth mentioning that the needling methods of
BL33 and BL35 to be used in our study are different
from the routine needling of these points. In routine
needling, both BL33 and BL35 should be needled per-
pendicularly to a depth of 0.8-1 cun, which is no more
than 25 mm. In our study, an oblique needling with a
depth of 50–60 mm is needed, since we hold that neural
regulation is the reason that acupuncture takes effect for
SUI. Deep needling of BL33 and BL35 can directly
stimulate the pudendal nerve and the anterior branches
of the third sacral nerve, and thus act to strengthen con-
traction of the pelvic floor muscle and the striated ureth-
ral sphincter.
Overall, acupuncture is a comparatively safe therapy
[22] and is gradually gaining acceptance in urology as an
effective treatment for erectile problems, lower urinary
tract symptoms and chronic prostatitis [23]. Since deep
needling and strong stimulation are used in the treat-
ment group, the evaluation of EA safety is necessary.
In conclusion, results of this trial are expected to con-
firm whether EA is effective for women with pure SUI,
and whether this effectiveness is an acupuncture efficacy
rather than a placebo effect.
Trial status
This trial is currently recruiting participants, and will be
completed by 31 December 2014.
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